Abstract
Prostate cancer is the second most common cause of death from cancer in U.S. men, and advanced, hormone–refractory disease is characterized by painful osteoblastic bone metastases. Endothelin–1, more commonly known as a potent vasoconstrictor, is a normal ejaculate protein that also stimulates osteoblasts. We show here that plasma immunoreactive endothelin concentrations are significantly elevated in men with metastatic prostate cancer and that every human prostate cancer cell line tested produces endothelin–1 messenger RNA and secretes immunoreactive endothelin. Exogenous endothelin–1 is a prostate cancer mitogen in vitro and increases alkaline phosphatase activity in new bone formation, indicating that ectopic endothelin–1 may be a mediator of the osteoblastic response of bone to metastatic prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wingo, P.A., Tong, T. & Bolden, S. Cancer statistics, 1995. CA Cancer J. Clin. 45, 8–30 (1995).
Huggins, C., Stevens, R.E. & Hodges, C.V. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43, 209–223 (1941).
Kelly, W.K. et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. clin. Oncol. 11, 607–615 (1993).
Yanagisawa, M. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411–415 (1988).
Casey, M.L., Byrd, W. & MacDonald, P.C. Massive amounts of immunoreactive endothelin in human seminal fluid. J. clin. Endoc. Metabol. 74, 223–225 (1992).
Langenstroer, P. et al. Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J. Urol. 149, 495–499 (1993).
Kobayashi, S. et al. Binding and functional properties of endothelin receptor subtypes in the human prostate. Molec. Pharmacol. 45, 306–311 (1994).
Kobayashi, S. et al. Localization of endothelin receptors in the human prostate. J. Urol. 151, 763–766 (1994).
Muldoon, L.L., Rodland, K.D., Forsythe, M.L. & Magun, B.E. Stimulation of phosphatidylinositol hydrolysis, diacylglycerol release, and gene expression in response to endothelin, a potent new agonist for fibroblasts and smooth muscle cells. J. biol. Chem. 264, 8529–8536 (1989).
Brown, K.D. & Littlewood, C.J. Endothelin stimulates DNA synthesis in Swiss 3T3 cells: Synergy with polypeptide growth factors. Biochem. J. 263, 977–980 (1989).
Shubeita, H.E. et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly and cardiac gene expression in ventricular myocytes. J. biol. Chem. 265, 20555–20562 (1990).
Battistini, B., Chailler, P., D'Orleans-Juste, P., Briere, N. & Sirois, P. Growth regulatory properties of endothelins. Peptides 14, 385–399 (1993).
Schirchiri, M. et al. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J. clin. Invest. 87, 1867–1871 (1991).
Takuwa, Y., Ohue, Y., Takuwa, N. & Yamashita, K. Endothelin-1 activates phospholipase C and mobilizes Ca2+ from extra- and intracellular pools in osteoblastic cells. Am. J. Physiol. 257, E797–803 (1989).
Takuwa, Y., Masaki, T. & Yamashita, K. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem. biophys. Res. Commun. 170, 998–1005 (1990).
Schvartz, I., Ittoop, O., Davidai, G. & Hazum, E. Endothelin rapidly stimulates tyrosine phosphorylation in osteoblast-like cells. Peptides 13, 159–163 (1992).
Shioide, M. & Noda, M. Endothelin modulates osteopontin and osteocalcin messenger ribonucleic acid expression in rat osteoblastic osteosarcoma cells. J. cell. Biochem. 53, 176–180 (1993).
Suzuki, N., Matsumoto, H., Kitada, C., Kimura, S. & Fujino, M. Production of endothelin-1 and big-endothelin-1 by tumour cells with epithelial-like morphology. J. Biochem. 106, 736–741 (1989).
Kusuhara, M. et al. Production of endothelin in human cancer cell lines. Cancer Res. 50, 3257–3261 (1990).
Schrey, M.P., Patel, K.V. & Tezapsidis, N. Bombesin and glucocorticoids stimulate human breast cancer cells to produce endothelin, a paracrine mitogen for breast stromal cells. Cancer Res. 52, 1786–1790 (1992).
Economos, K., MacDonald, P.C. & Casey, M.L. Endothelin-1 gene expression and biosynthesis in human endometrial HEC-1A cancer cells. Cancer Res. 52, 554–557 (1992).
Yamashita, J. et al. Abundant expression of immunoreactive endothelin-1 in mammary phyllodes tumour: Possible role of endothelin 1 in the growth of stromal cells in phyllodes tumour. Cancer Res. 52, 4046–4049 (1992).
Yamashita, J. et al. Interleukin 6 stimulates the production of immunoreactive endothelin 1 in human breast cancer cells. Cancer Res. 53, 464–467 (1993).
Inoue, A. et al. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. natn. Acad. Sci. U.S.A. 86, 2863–2867 (1989).
Takasaki, C., Yanagisawa, M., Kimura, S., Goto, K. & Masaki, T. Similarity of endothelin to snake venom toxin. Nature 335, 303 (1988).
Kochva, E., Bdolah, A. & Wollberg, Z. Sarafotoxins and endothelins: Evolution, structure and function. Toxicon 31, 541–568 (1993).
Kochva, E., Viljoen, C.C. & Botes, D.P. A new type of toxin in the venom of snakes of the genus Atractaspis (Atractaspidinae). Toxicon 20, 581–592 (1982).
Dahlof, B., Gustafsson, D., Hedner, T., Jern, S. & Hansson, L. Regional haemodynamic effects of endothelin-1 in rat and man: Unexpected adverse reactions. J. Hypertens. 8, 811–817 (1990).
Eisenberger, M.A. et al. Suramin, an active drug for prostate cancer: Interim observations in a phase I trial. J. natn. Cancer Inst. 85, 611–621 (1993).
Yamane, K. et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J. Rheumatol. 19, 1566–1571 (1992).
Ogawa, S., Zhang, J. & Yuge, K. Increased plasma endothelin-1 concentration in Kawasaki disease. J. Cardiovasc. Pharmacol. 22, S364–366 (1993).
Cernacek, P. & Stewart, D.J. Immunoreactive endothelin in human plasma: Marked elevations in patients in cardiogenic shock. Biochem. biophys. Res. Commun. 161, 562–567 (1989).
Yasuda, M. et al. Circulating immunoreactive endothelin in ischemic heart disease. Am. Heart J. 119, 801–806 (1990).
Lerman, A. et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. New Engl. J. Med. 325, 997–1001 (1991).
Yokokawa, K. et al. Hypertension associated with endothelin-secreting malignant hemangioendpthelioma. Ann. intern. Med. 114, 213–215 (1991).
Yokokawa, K. et al. Endothelin-secreting tumour. J. Cardiovasc. Pharmacol. 17, S398–S401 (1991).
Cacoub, P., Dorent, R., Nataf, P. & Carayon, A. Endothelin-1 in pulmonary hypertension. New Engl. J. Med. 329, 1967–1968 (1993).
Pittet, J.F. et al. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann. Surg. 213, 261–264 (1991).
Wei, C.M. et al. Endothelin in human congestive heart failure. Circulation 89, 1580–1586 (1994).
Moore, K. et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. New Engl. J. Med. 327, 1774–1778 (1992).
Rolinski, B., Sadri, I., Bogner, J. & Goebel, F.D. Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res. exp. Med. 194, 9–24 (1994).
Nakamuta, M. et al. High plasma concentrations of endothelin-like immunoreactivities in patients with hepatocellular carcinoma. Am. J. Gastroenterol. 88, 248–252 (1993).
Moller, S., Emmeluth, C. & Henriksen, J.H. Elevated circulating plasma endothelin-1 concentrations in cirrhosis. J. Hepatol. 19, 285–290 (1993).
MacCumber, M.W., Ross, C.A., Glaser, B.M. & Snyder, S.H. Endothelin: Visualization of mRNAs by in situ hybridization provides evidence for local action. Proc. natn. Acad. Sci. U.S.A. 86, 7285–7289 (1989).
Wagner, O.F. et al. Polar secretion of endothelin-1 by cultured endothelial cells. J. biol. Chem. 267, 16066–16088 (1992).
Rubanyi, G.M. & Parker Botelho, L.H. Endothelins. FASEB J. 5, 2713–2720 (1991).
Warner, T.D., Battistini, B., Doherty, A.M. & Corder, R. Endothelin receptor antagonists: Actions and rationale for their development. Biochem. Pharmacol. 48, 625–635 (1994).
Battistini, B., D'Orleans-Juste, P. & Sirois, P. Endothelins: Circulating plasma levels and presence in other biologic fluids. Lab. Invest. 68, 600–628 (1993).
Simonson, M.S. & Dunn, M.J. Cellular signaling by peptides of the endothelin gene family. FASEB J. 4, 2989–3000 (1990).
Erdos, E.G., Schulz, W.W., Gafford, J.T. & Defendini, R. Neutral metalloendopeptidase in human male genital tract: Comparison to angiotensin I-converting enzyme. Lab. Invest. 52, 437–447 (1985).
Papandreou, C. et al. Loss of neutral endopeptidase in androgen independent prostate cancers. Proc. Am. Assoc. Cancer Res. 36, 268 (1995).
Stamey, T.A. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med. 317, 909–916 (1987).
Oesterling, J.E. et al. Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol. 139, 766–779 (1988).
Rubin, S.A. & Levin, E.R. The endocrinology of vasoactive peptides: Synthesis to function. J. clin. Endocr. Metabol. 78, 6–10 (1994).
Polderman, K.H. et al. Influence of sex hormones on plasma endothelin levels. Ann. intern. Med. 118, 429–432 (1993).
Scher, H.I. & Chung, L.W.K. Bone metastases: Improving the therapeutic index. Semin. Oncol. 21, 630–656 (1994).
Alam, A.S.M.T. et al. Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: Implications for the vascular control of bone resorption. Endocrinology 130, 3617–3624 (1992).
Charache, S. & Page, D.L. Infarction of bone marrow in the sickle cell disorders. Ann. intern. Med. 67, 1195–1200 (1967).
Platt, O.S. et al. Pain in sickle cell disease: Rates and risk factors. New Engl. J. Med. 325, 11–16 (1991).
Lam, H.C. et al. Immunoreactive endothelin in human plasma, urine, milk, and saliva. J. Cardiovasc. Pharmacol. 17, S390–393 (1991).
Reddi, A.H. & Huggins, C. Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. Proc. natn. Acad. Sci. U.S.A. 69, 1601–1605 (1972).
Reddi, A.H. & Sullivan, N.E. Matrix-induced endochondral bone differentiation influence of hypophysectomy, growth hormone, and thyroid-stimulating hormone. Endocrinology 107, 1291–1299 (1980).
Lowry, O.H., Rosebrough, N.J., Farr, A.L. & Randall, R.J. Protein measurement with the Folin phenol reagent. J. biol. Chem. 193, 265 (1951).
Kramer, C.Y. Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 12, 307–310 (1956).
Kruskal, W.H. & Wallis, W.A. Use of ranks in one-criterion variance analysis. J. Am. Stat. Assoc. 47, 583–621 (1952). Addendum, ibid. 48, 907–911 (1953).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nelson, J., Hedican, S., George, D. et al. Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1, 944–949 (1995). https://doi.org/10.1038/nm0995-944
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0995-944
This article is cited by
-
Targeting the Endothelin-1 pathway to reduce invasion and chemoresistance in gallbladder cancer cells
Cancer Cell International (2023)
-
Evolving cancer–niche interactions and therapeutic targets during bone metastasis
Nature Reviews Cancer (2022)
-
Treatment and trials in non-metastatic castration-resistant prostate cancer
Nature Reviews Urology (2021)
-
Endothelin-1 enhances acid-sensing ion channel currents in rat primary sensory neurons
Acta Pharmacologica Sinica (2020)
-
Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis
Scientific Reports (2020)